OA11231A - Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer - Google Patents

Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer Download PDF

Info

Publication number
OA11231A
OA11231A OA9900276A OA9900276A OA11231A OA 11231 A OA11231 A OA 11231A OA 9900276 A OA9900276 A OA 9900276A OA 9900276 A OA9900276 A OA 9900276A OA 11231 A OA11231 A OA 11231A
Authority
OA
OAPI
Prior art keywords
alkyl
phenyl
halo
amino
hydroxy
Prior art date
Application number
OA9900276A
Other languages
English (en)
Inventor
Shama Mohammed Kajiiji
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11231A publication Critical patent/OA11231A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA9900276A 1997-06-16 1999-12-10 Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer OA11231A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16

Publications (1)

Publication Number Publication Date
OA11231A true OA11231A (en) 2003-05-26

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900276A OA11231A (en) 1997-06-16 1999-12-10 Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer

Country Status (37)

Country Link
EP (1) EP0986387B1 (no)
JP (1) JP3713051B2 (no)
KR (1) KR100392573B1 (no)
CN (1) CN1259868A (no)
AP (1) AP9801261A0 (no)
AR (1) AR013090A1 (no)
AT (1) ATE235905T1 (no)
BG (1) BG103946A (no)
BR (1) BR9810616A (no)
CA (1) CA2294399C (no)
CO (1) CO4950607A1 (no)
DE (1) DE69812933T2 (no)
DK (1) DK0986387T3 (no)
DZ (1) DZ2518A1 (no)
EA (1) EA199901043A1 (no)
ES (1) ES2196559T3 (no)
GT (1) GT199800081A (no)
HN (1) HN1998000091A (no)
HR (1) HRP980328B1 (no)
HU (1) HUP0004624A3 (no)
ID (1) ID23014A (no)
IL (1) IL132765A0 (no)
IS (1) IS5259A (no)
MA (1) MA24569A1 (no)
NO (1) NO996206L (no)
NZ (1) NZ500662A (no)
OA (1) OA11231A (no)
PA (1) PA8453601A1 (no)
PE (1) PE82899A1 (no)
PL (1) PL337651A1 (no)
PT (1) PT986387E (no)
SK (1) SK169699A3 (no)
TN (1) TNSN98088A1 (no)
TR (1) TR199903074T2 (no)
UA (1) UA57081C2 (no)
WO (1) WO1998057633A1 (no)
ZA (1) ZA985182B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1077949A2 (en) 1998-05-12 2001-02-28 Warner-Lambert Company Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer
AU6256499A (en) * 1998-09-24 2000-04-10 Merck & Co., Inc. A method of treating cancer
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CA2432137C (en) 2000-12-19 2010-12-21 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
JP4092203B2 (ja) 2000-12-21 2008-05-28 ニトロメッド，インク． 新規のシクロオキシゲナーゼ２選択的阻害剤としての置換アリール化合物、組成物、および使用方法
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083985A (en) * 1995-08-09 2000-07-04 Banyu Pharmaceutical Co., Ltd. Medicinal composition

Also Published As

Publication number Publication date
AU7445998A (en) 1999-01-04
AU724676B2 (en) 2000-09-28
CO4950607A1 (es) 2000-09-01
JP3713051B2 (ja) 2005-11-02
PL337651A1 (en) 2000-08-28
KR20010013839A (ko) 2001-02-26
DE69812933D1 (de) 2003-05-08
ZA985182B (en) 1999-12-17
EP0986387A1 (en) 2000-03-22
HUP0004624A2 (hu) 2001-10-28
PA8453601A1 (es) 2000-05-24
HRP980328A2 (en) 1999-04-30
HRP980328B1 (en) 2002-06-30
EA199901043A1 (ru) 2000-06-26
CN1259868A (zh) 2000-07-12
DZ2518A1 (fr) 2003-02-01
MA24569A1 (fr) 1998-12-31
BR9810616A (pt) 2000-09-12
PT986387E (pt) 2003-06-30
DK0986387T3 (da) 2003-07-14
IL132765A0 (en) 2001-03-19
AP9801261A0 (en) 1999-12-11
NO996206D0 (no) 1999-12-15
HUP0004624A3 (en) 2002-11-28
UA57081C2 (uk) 2003-06-16
TNSN98088A1 (fr) 2005-03-15
NO996206L (no) 2000-02-15
ATE235905T1 (de) 2003-04-15
SK169699A3 (en) 2000-06-12
DE69812933T2 (de) 2003-11-06
WO1998057633A1 (en) 1998-12-23
IS5259A (is) 1999-11-19
PE82899A1 (es) 1999-08-26
CA2294399A1 (en) 1998-12-23
CA2294399C (en) 2004-03-16
JP2000513031A (ja) 2000-10-03
HN1998000091A (es) 1999-09-29
NZ500662A (en) 2001-10-26
AR013090A1 (es) 2000-12-13
BG103946A (bg) 2000-07-31
EP0986387B1 (en) 2003-04-02
GT199800081A (es) 1999-12-07
TR199903074T2 (xx) 2000-05-22
ID23014A (id) 1999-12-30
ES2196559T3 (es) 2003-12-16
KR100392573B1 (ko) 2003-07-23

Similar Documents

Publication Publication Date Title
US7307071B2 (en) RAF-MEK-ERK pathway inhibitors to treat cancer
US20050014783A1 (en) Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy
OA11231A (en) Farnesyl transferase inhibtors in combinatin with hmg coa reductase inhibitors for the treatment of cancer
KR101354237B1 (ko) 골수종 치료를 위한 ｈｄａｃ 저해제의 용도
MA27703A1 (fr) Derives de diazepino-indole servant d'inhibiteurs de kinases
TWI786723B (zh) 噠嗪并吲哚衍生物及其用途
US11129830B2 (en) PAC-1 combination therapy
EP2182941B1 (en) Multikinase inhibitors for use in the treatment of cancer
Ory et al. Blocking HSP90 addiction inhibits tumor cell proliferation, metastasis development, and synergistically acts with zoledronic acid to delay osteosarcoma progression
JP2007063288A (ja) エンドセリンアンタゴニストを用いる癌及び癌関連痛の治療方法
US20060178348A1 (en) Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an NSAID
Tamanoi et al. Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions
Chin et al. Sodium vanadate inhibits apoptosis in malignant glioma cells: a role for Akt/PKB
AU724676C (en) Farnesyl transferase inhibitors in combination with hmg CoA reductase inhibitors for the treatment of cancer
US20030114503A1 (en) Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
WO2005105078A1 (en) Indole derivatives useful for treating resistance to antitumour agents
US10196378B2 (en) Inhibitors of BCR-ABL mutants and use thereof
MXPA99011798A (en) FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER
US20020151563A1 (en) Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
CZ448699A3 (cs) Inhibitory farnesyltransferasy v kombinaci s inhibitory HMG CoA reduktasy pro léčení rakoviny
WO2021086912A1 (en) Combined pikfyve and p38 map kinase inhibition for treating cancer
US5179113A (en) Treatment of central nervous disorders with imidazole compounds
WO2002002116A2 (en) Therapeutic treatment of cancer with a protein kinase c inhibitor
CA2120234A1 (en) 2-aminopropan-1,3-diol chemotherapeutic agents
Halabi A Synthetic Lethal Screen for NF-kB-Dependent Plasma Cell Disorders